When a research design involves more than one hypothesis test, the probability of falsely rejecting at least one true null hypothesis escalates rapidly. A single experiment running ten tests at α = 0.05 carries a cumulative 40% chance of producing a spurious significant result — a statistical artifact, not a genuine discovery.
The Bonferroni correction is the most widely applied safeguard against this inflated error rate. By dividing the original significance level by the total number of comparisons, it recalibrates each individual test to a stricter threshold, preserving the overall Family-Wise Error Rate (FWER) at the desired level. This calculator automates that adjustment and provides complementary metrics — including the Šidák correction, uncorrected FWER, and expected false positive count — enabling researchers to evaluate both the necessity and the cost of correction before committing to a decision framework.
Required Project Parameters
Before performing any correction, the following analytical variables must be established:
- Initial Significance Level (α): The target Family-Wise Error Rate prior to correction. The conventional default in peer-reviewed research is 0.05, though exploratory studies may use 0.10 and confirmatory clinical trials often require 0.01 or stricter.
- Number of Comparisons (m): The total count of simultaneous hypothesis tests conducted within the experiment. This includes all pairwise comparisons, subgroup analyses, and endpoint evaluations — not merely the "primary" tests.
- Observed P-Values (optional): A comma-separated list of empirical p-values obtained from actual test statistics. When provided, each value is evaluated against both the uncorrected and corrected thresholds, producing a direct count of which findings survive adjustment.
The Probabilistic Architecture of Multiple Testing Corrections
Bonferroni Adjusted Threshold
The Bonferroni correction applies the simplest possible linear rescaling to the original significance level. For $m$ simultaneous tests at a desired FWER of $\alpha$, the adjusted per-comparison threshold $\alpha_{adj}$ is:
$$\alpha_{adj} = \frac{\alpha}{m}$$
This formulation derives directly from Boole's inequality (the union bound), which states that the probability of the union of events is at most the sum of their individual probabilities. The critical mathematical property is that this bound holds regardless of the dependence structure among tests — whether they are fully independent, partially correlated, or even perfectly dependent.
For a standard scenario of $\alpha = 0.05$ and $m = 10$ comparisons, the corrected threshold becomes $\alpha_{adj} = 0.005$. Each individual test must now achieve a p-value below 0.005 to be declared significant.
Uncorrected Family-Wise Error Rate
Without any correction, the probability of committing at least one Type I error across $m$ independent tests is computed as the complement of the probability that all tests correctly retain their null hypotheses:
$$FWER_{uncorrected} = 1 - (1 - \alpha)^{m}$$
This exponential accumulation is the core problem that multiple testing corrections exist to solve. At $\alpha = 0.05$ and $m = 20$, the uncorrected FWER reaches approximately 0.642 — a near coin-flip probability of at least one false discovery contaminating the results.
Šidák Correction: The Exact Probabilistic Alternative
While Bonferroni provides a conservative upper bound, the Šidák correction delivers the mathematically exact per-test threshold for strictly independent tests. The adjusted alpha is derived by inverting the FWER equation:
$$\alpha_{Šidák} = 1 - (1 - \alpha)^{\frac{1}{m}}$$
Technically, the Bonferroni formula $\alpha / m$ is a first-order Taylor series approximation of the Šidák equation. For small values of $\alpha$ and moderate $m$, the two converge closely. However, as $m$ grows large, the Šidák correction yields a slightly less conservative (more powerful) threshold. Despite this mathematical superiority under independence, Bonferroni remains the industry standard precisely because its reliance on Boole's inequality guarantees valid FWER control even when tests exhibit arbitrary dependence — a guarantee the Šidák method cannot safely make for correlated test families.
Expected False Positives and Adjusted Confidence
Two additional diagnostic metrics complete the analytical picture. The expected number of false positives under the null (no correction applied) is:
$$E[\text{False Positives}] = m \times \alpha$$
This represents the statistical expectation — the long-run average count of Type I errors. For 10 tests at $\alpha = 0.05$, the expected count is 0.5 false positives per experiment.
The adjusted confidence level translates the corrected per-test threshold into percentage form:
$$\text{Adjusted Confidence} = (1 - \alpha_{adj}) \times 100\%$$
At $\alpha_{adj} = 0.005$, this yields a per-test confidence of 99.5%, illustrating the dramatic tightening of evidential standards imposed by correction.
Correction Severity Across Experimental Scales
The following reference tables demonstrate how key correction metrics evolve as the number of simultaneous comparisons increases — a critical consideration when designing multi-arm trials, factorial experiments, or large-scale screening studies.
Bonferroni and Šidák Thresholds by Comparison Count (α = 0.05)
| Comparisons (m) | Bonferroni α_adj | Šidák α_adj | Uncorrected FWER | Expected False Positives |
|---|---|---|---|---|
| 3 | 0.01667 | 0.01695 | 0.1426 | 0.15 |
| 5 | 0.01000 | 0.01021 | 0.2262 | 0.25 |
| 10 | 0.00500 | 0.00512 | 0.4013 | 0.50 |
| 20 | 0.00250 | 0.00256 | 0.6415 | 1.00 |
| 50 | 0.00100 | 0.00100 | 0.9231 | 2.50 |
| 100 | 0.00050 | 0.00050 | 0.9941 | 5.00 |
| 500 | 0.00010 | 0.00010 | ≈ 1.0000 | 25.00 |
| 1,000 | 0.00005 | 0.00005 | ≈ 1.0000 | 50.00 |
Correction Method Selection Guide by Research Domain
| Domain | Typical m Range | Recommended Primary Correction | Rationale |
|---|---|---|---|
| Randomized Clinical Trials | 2–10 | Bonferroni | Regulatory acceptance (FDA/EMA); conservative control appropriate for patient safety |
| Behavioral Psychology (ANOVA post-hoc) | 3–15 | Bonferroni or Holm step-down | Standard practice; Holm is uniformly more powerful |
| Neuroimaging (fMRI) | 10,000–100,000+ | FDR (Benjamini-Hochberg) or cluster-based | Bonferroni is prohibitively conservative for voxel-wise testing |
| Genome-Wide Association Studies | 500,000–5,000,000 | Bonferroni (5 × 10⁻⁸ convention) or FDR | Bonferroni-derived genome-wide threshold is field standard |
| A/B Testing (Digital Products) | 2–20 | Šidák or sequential methods | Tests often independent; sequential designs allow early stopping |
| Ecological Field Studies | 5–50 | FDR (Benjamini-Hochberg) | Exploratory nature prioritizes discovery over strict error control |
Impact on Statistical Power (1 − β) at Varying Effect Sizes
| Effect Size (Cohen's d) | Power at α = 0.05 (n = 50/group) | Power at α = 0.005 (Bonferroni, m = 10) | Power Loss (%) |
|---|---|---|---|
| 0.2 (Small) | 0.169 | 0.033 | −80.5% |
| 0.5 (Medium) | 0.697 | 0.338 | −51.5% |
| 0.8 (Large) | 0.968 | 0.814 | −15.9% |
| 1.0 (Very Large) | 0.997 | 0.970 | −2.7% |
This third table quantifies the conservativeness trade-off — the central tension in every multiple testing correction decision. Bonferroni dramatically erodes the ability to detect small and medium effects. In fields with inherently modest effect sizes (behavioral science, social epidemiology), this power degradation can render an otherwise well-designed study functionally incapable of detecting real phenomena, effectively converting a Type I error control into a Type II error inflator.
Interpreting Corrected Results in Applied Research
The Conservativeness Problem in Correlated Data
The Bonferroni correction assumes, at minimum, that the inequality $P(\bigcup A_i) \leq \sum P(A_i)$ provides a useful bound. In practice, this bound becomes increasingly loose as tests become more positively correlated. Consider fMRI neuroimaging, where adjacent brain voxels share hemodynamic signals — testing 100,000 voxels at a Bonferroni-corrected threshold of $\alpha_{adj} = 5 \times 10^{-7}$ suppresses activation clusters that represent genuine neural responses. The effective FWER in such scenarios is far below the nominal $\alpha$, meaning the correction is controlling an error rate that was never actually at risk of reaching the nominal level.
This is why domain-specific alternatives have emerged. The Holm-Bonferroni step-down procedure provides uniformly greater power while still controlling FWER. It ranks p-values and applies progressively less strict thresholds as tests are sequentially rejected — a strictly superior approach with no additional assumptions.
When Bonferroni Becomes Impractical: The Shift to False Discovery Rate
For experiments where $m$ exceeds approximately 1,000 comparisons, the Bonferroni threshold contracts to levels where even biologically meaningful signals cannot survive correction. Genome-Wide Association Studies (GWAS) routinely evaluate millions of genetic variants, producing a conventional Bonferroni threshold of $5 \times 10^{-8}$ — a standard that, while field-accepted, demands enormous sample sizes (often exceeding 100,000 participants) to achieve adequate power for common variants with small effect sizes.
The Benjamini-Hochberg (BH) procedure controls a fundamentally different quantity: the False Discovery Rate (FDR), defined as the expected proportion of rejected hypotheses that are falsely rejected. Rather than demanding that the probability of any false positive remain below $\alpha$, FDR tolerates a controlled fraction of false positives among discoveries. Setting FDR at 0.05 accepts that approximately 5% of reported discoveries may be false — a far more pragmatic standard for discovery-oriented research. This distinction is critical: FWER answers "did I make any mistake?" while FDR answers "what fraction of my discoveries are mistakes?"
Practical Decision Framework
The choice of correction method hinges on the consequences of error types in the specific research context:
- High cost of false positives (drug approval, engineering safety margins, legal forensic evidence): Apply Bonferroni or Holm. The conservatism is the feature, not the bug.
- High cost of false negatives (early-stage drug screening, ecological monitoring, exploratory genomics): Apply Benjamini-Hochberg FDR control. Missing a genuine signal is more damaging than including a few false leads.
- Balanced costs with moderate m (psychology experiments, clinical subgroup analyses with 3–15 comparisons): Apply Holm-Bonferroni for improved power without sacrificing FWER control.
Frequently Asked Questions
The correction divides $\alpha$ by $m$, producing a threshold that shrinks linearly with the number of tests. At $m = 1{,}000$ and $\alpha = 0.05$, each test must achieve $p < 0.00005$ — a standard so extreme that only massive effect sizes or enormous sample sizes can produce detectable signals.
The deeper issue is that Bonferroni controls the probability of even one false positive across all tests. As $m$ grows, this guarantee becomes increasingly expensive in terms of statistical power. For discovery-oriented research (genomics, proteomics, high-throughput screening), the Benjamini-Hochberg FDR procedure provides a more calibrated trade-off by controlling the proportion of false discoveries rather than their mere existence.
Both aim to control FWER, but they differ in mathematical derivation and applicability. Šidák solves $1 - (1 - \alpha_{adj})^{m} = \alpha$ exactly, yielding a marginally higher (less conservative) per-test threshold than Bonferroni's $\alpha / m$.
However, the Šidák correction requires strict independence among all $m$ tests. When test statistics are correlated — as occurs in repeated-measures designs, spatially structured data, or hierarchical models — the Šidák threshold may fail to control FWER at the nominal level. Bonferroni, by relying on Boole's inequality rather than independence assumptions, provides valid FWER control under any dependence structure, which is why regulatory bodies and conservative research frameworks prefer it despite its slightly lower power.
This question touches one of the most debated issues in applied statistics. Strictly, Bonferroni correction addresses the multiplicity problem inherent in simultaneous testing — it should be applied whenever multiple tests are evaluated within the same experiment, regardless of whether they were pre-specified.
In practice, however, many statisticians distinguish between confirmatory and exploratory analyses. A single pre-registered primary endpoint in a clinical trial may not require correction if it was genuinely the sole hypothesis of interest. But when a study protocol specifies three co-primary endpoints or multiple secondary endpoints, correction is both statistically necessary and regulatorily mandated by agencies such as the FDA and EMA. The safest principle: if results from multiple tests will jointly influence a single conclusion or decision, apply correction. If each test addresses a genuinely independent scientific question, correction may be overly conservative — but this argument requires transparent justification in the analysis plan.
Precision Through Automated Correction Over Manual Calculation
Manual computation of Bonferroni-adjusted thresholds introduces two categories of risk. The first is arithmetic error — dividing $\alpha$ by the wrong $m$, miscounting the total number of comparisons (a surprisingly common mistake in factorial designs where interaction terms multiply the test count), or misapplying the correction to a subset rather than the full family of tests. The second is interpretive error — comparing observed p-values against an uncorrected threshold while believing correction was applied, or confusing per-comparison and per-family error rates in reporting.
Automated calculation eliminates both failure modes. It enforces consistent application of the correction formula across all comparisons, simultaneously computes complementary diagnostics (Šidák threshold, uncorrected FWER, expected false positive count), and enables direct evaluation of empirical p-values against corrected thresholds. This systematic approach ensures that the published statistical conclusions accurately reflect the evidential standards claimed in the methods section — a requirement that peer reviewers and regulatory auditors increasingly verify.